Alivira Animal Health USA LLC
Balance Sheet as at 31 March 2026
Amounts in USD ($) unless otherwise stated

Particulars	Note No.	As at 31 March'26 (USD)	As at 31 March'25 (USD)
ASSETS			
Current assets			
(a) Financial Assets			
(i) Cash and cash equivalents	3	13,045	42,600
Total current assets		**13,045**	**42,600**
TOTAL ASSETS		**13,045**	**42,600**
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	4	24,47,385	19,37,410
(b) Other Equity	5		
Retained Earnings		(30,42,598)	(25,19,781)
Other Reserves		5,19,889	5,09,666
Total equity		**(75,324)**	**(72,705)**
Current liabilities			
(a) Financial Liabilities			
(i) Trade payables	6	-	76,758
(ii) Other financial liabilities	7	52,824	-
(b) Other current liabilities	8	35,545	38,547
Total current liabilities		**88,369**	**1,15,305**
TOTAL EQUITY AND LIABILITIES		**13,045**	**42,600**

As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S

Avneep L Mehta
Partner
Membership no. 225441

M O J & ASSOCIATES * BENGALURU * CHARTERED ACCOUNTANTS

Date: 18 May 2026
Place: Bengaluru

For and on behalf of the Board of Directors

Alan Kelly
Authorised Signatory
Vice President

Date: 18 May 2026
Place: Illinois, USA

Alivira Animal Health USA LLC
Statement of Profit and Loss for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

	Particulars	Note No	Period ended 31 March 2026	Year ended 31 March 2025
			(USD)	(USD)
(I)	Revenue From Operations		-	-
(II)	Other Income		-	-
(III)	**Total income (I+ II)**		-	-
(IV)	EXPENSES			
	Employee benefits expense	9	4,02,917	4,72,993
	Finance costs	10	9,286	3,537
	Other expenses	11	1,10,614	60,775
	Total expenses (IV)		5,22,817	5,37,305
(V)	Profit before tax (III- IV)		**(5,22,817)**	**(5,37,305)**
(VI)	Tax expense		-	-
(VII)	Profit after tax (V- VI)		**(5,22,817)**	**(5,37,305)**
	Earnings per equity share			
	(1) Basic		(0.21)	(0.28)
	(2) Diluted		(0.21)	(0.28)

As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S

Avneep L Mehta
Partner
Membership no. 225441

MOJ & ASSOCIATES BENGALURU CHARTERED ACCOUNTANTS

For and on behalf of the Board of Directors

Alan Kelly
Authorised Signatory
Vice President

Date: 18 May 2026
Place: Bengaluru

Date: 18 May 2026
Place: Illinois, USA

Alivira Animal Health USA LLC
Statement of cash flows for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

Particulars		**Year ended 31 March 2026**	**Year ended 31 March 2025**
Cash flow from operating activities			
Net loss before tax		**(5,22,817)**	**(5,37,305)**
Adjustments for:			
Share based payment to employees		10,223	36,725
Finance cost		-	-
Operating loss before working capital changes		**(5,12,594)**	**(5,00,579)**
Changes in working capital			
Increase in trade and other payables		-26,935	79,695
Net change in working capital		**-26,935**	**79,695**
Cash (used in) operations		**(5,39,529)**	**(4,20,885)**
Direct taxes (paid)/refund		-	-
Net cash (used in) operations	**A**	**(5,39,529)**	**(4,20,885)**
Net cash generated from investing activities	**B**	**-**	**-**
Cash flow from financing activities			
Proceeds from Share capital		5,09,975	4,18,224
Interest paid		-	-
Net cash generated from financing activities	**C**	**5,09,975**	**4,18,224**
Net increase/(decrease) in cash and cash equivalents during the year/ period	**(A+B+C)**	**(29,555)**	**-2,661**
Cash and cash equivalents at the beginning of the year (refer note 3)		42,600	45,261
Cash and cash equivalents at the end of the year		**13,045**	**42,600**
Significant Accounting Policies	**2**		

The accompanying notes are an integral part of the financial statements.

As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S

MOJ & ASSOCIATES * BENGALURU * CHARTERED ACCOUNTANTS

Avneep L Mehta
Partner
Membership no. 225441

Date: 18 May 2026
Place: Banglore

Alan Kelly
Authorised Signatory
Vice President

Date: 18 May 2026
Place: Illinois, USA

Alivira Animal Health USA LLC
Statement of Changes in Equity (SOCIE) for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

(a) Equity share capital	**As at 31 March 2026**		**As at 31 March 2025**	
	No. of Shares	**Amount**	**No. of Shares**	**Amount**
Balance at the beginning of the reporting year	19,37,410	19,37,410	14,82,460	14,82,460
Issued during the year	5,09,975	5,09,975	4,54,950	4,54,950
Balance at the end of the reporting year	**24,47,385**	**24,47,385**	**19,37,410**	**19,37,410**

(b) Other equity

Retained Earnings	**As at 31 March 2026**	**As at 31 March 2025**
Opening balance	(25,19,780)	(19,82,476)
Add:Loss for the year	(5,22,817)	(5,37,305)
Closing balance	**(30,42,597)**	**(25,19,780)**

Share Options Outstanding Account	**As at 31 March 2026**	**As at 31 March 2025**
Opening balance	5,09,666	4,72,941
Add:Loss for the year	10,223	36,725
Closing balance	**5,19,889**	**5,09,666**

The accompanying notes are an integral part of the financial statements.

As per our report of event date
For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S

MOJ & ASSOCIATES BENGALURU CHARTERED ACCOUNTANTS

Avneep L Mehta
Partner
Membership no. 225441

Date: 18 May 2026
Place: Banglore

Alan Kelly
Authorised Signatory
Vice President

Date: 18 May 2026
Place: Illinois, USA

Alivira Animal Health USA LLC
Notes forming part of the financial statements for the year ended 31 March, 2026

Note : Material accounting policies

1 Corporate information

The Company incorporated on 25 March 2020, is a private company limited by shares.The company seeks to develop, manufacture and sell veterinary products, including both active pharmaceutical ingredients (API) and formulations to cater to the global market.

2 Significant accounting policies

2.1 Basis of accounting and preparation of financial statements

The Financial Statements have been prepared on accrual basis under the historical cost convention.

The financial statements of Alivira Animal Health USA LLC ('the Company') have been prepared, in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015.

2.2 Functional and Presentation Currency

These financial statements are presented in US Dollars ("$") which is the Company's functional currency. The Directors of the Company believe that $ most faithfully represents the economic effects of the underlying transactions, events and conditions.

2.3 Employee benefits

Short term employee benefits are accrued based on the terms of employment when services are rendered by the employees and charged as an expense to the statement of profit and loss.

2.4 Earnings per share (EPS)

In determining the Earnings per share, the Company considers the net profit after tax. The number of shares used in computing Basic Earnings per share is the weighted average number of equity shares outstanding during the period. The number of shares used in computing Diluted Earnings per share comprises the weighted average number of equity shares considered for deriving Basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date.

2.5 Provisions and contingencies

A provision is recognized when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate. Contingent liabilities are not recognized but are disclosed in the notes to financial statements.

2.6 Use of estimates

The preparation of the financial statements in conformity with the Accounting Standards generally accepted in India requires that the Management makes estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Management believes that the estimates used in preparation of financial statement are prudent and reasonable. Actual results could differ from those estimates and the estimates are recognised in the period in which the results are known/materialise.

2.7 Segment

Segments have been identified taking into account the nature of services, the differing risks and returns, the organizational structure and the internal reporting system.

2.8 Cash flow statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities are segregated based on the available information.

2.9 Cash and cash equivalents (for purposes of cash flow statement)

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

2.10 Operating cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

2.11 Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current / non-current classification.
An asset is treated as current when:
- It is expected to be realised or intended to be sold or consumed in normal operating cycle,
- It is held primarily for the purpose of trading,
- It is expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.
A liability is current when:
- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading,
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting.

All other liabilities are classified as non-current.
Deferred tax assets and liabilities are classified as non-current assets and liabilities.
The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.
The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

MOJ & ASSOCIATES * CHARTERED ACCOUNTANTS * BENGALURU

Alivira Animal Health USA LLC
Notes to the financial statements for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

Note no	Particulars	As at 31 Mar'26 USD	As at 31 Mar'25 USD
3	**Cash and cash equivalents**		
	Balances with banks		
	- In current accounts	13,045	42,600
		13,045	42,600
4	**Share capital**		
	Equity share capital	24,47,385	19,37,410
	Share Application money	-	-
		24,47,385	19,37,410
5	**a) Retained Earnings**		
	Opening Balance	-25,19,781	-19,82,476
	Add: Loss for the year	-5,22,817	-5,37,305
	Closing balance	-30,42,598	-25,19,781
	ii) Other Reserves		
	Share Options Outstanding Account	5,19,889	5,09,666
		5,19,889	5,09,666
	Other Equity (Total)	-25,22,709	-20,10,115
6	**Trade payable**		
	Trade payable	-	76,758
		-	76,758

As on 31 March 2026

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled	Not due	1-2 years	2-3 years	More than 3 years	
Trade Payables	-	-	-	-	-	-
Total	-	-	-	-	-	-

As on 31 March 2025

Particulars	Outstanding for following periods from due date of payment					Total
	Unbilled	Not due	1-2 years	2-3 years	More than 3 years	
Trade Payables	-	76,758	-	-	-	76,758
Total	-	76,758	-	-	-	76,758

Note no	Particulars	As at 31 Mar'26 USD	As at 31 Mar'25 USD
7	**Current - Other financial liabilities**		
	Employee benefits payables	52,824	-
		52,824	-
8	**Other current liabilities**		
	Statutory remittances	35,545	38,547
		35,545	38,547

MOJ & ASSOCIATES
BENGALURU
CHARTERED ACCOUNTANTS

Alivira Animal Health USA LLC
Notes to the financial statements for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

Note no	Particulars	USD YTD Mar'26	USD YTD Mar'25
9	**Employee benefits expense**		
	Salaries and wages	3,76,682	4,02,369
	Contribution to provident and other funds	-	-
	Expense on employee stock based compensation*	10,223	36,725
	Staff welfare expenses	16,012	33,899
	Gratuity	-	-
		4,02,917	**4,72,993**
10	**Finance costs**		
	Interest expense	-	-
	Other borrowing costs	9,286	3,537
		9,286	**3,537**
11	**Other expenses**		
	Legal and Professional charges	99,505	49,310
	Insurance	-	-
	Rates and taxes	-	1,265
	Other expenses	11,109	10,200
		-	
		1,10,614	**60,775**

MOJ & ASSOCIATES
BENGALURU
CHARTERED ACCOUNTANTS

Alivira Animal Health USA LLC
Notes to the financial statements for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

11 Related Party Disclosures:

A List of related parties:

i) Holding company:

Alivira Animal Health Limited, Ireland

Alivira Animal Health Limited, India (Holding company of Alivira Animal Health Limited, Ireland)

Viyash Scientific Limited, India (Ultimate Holding Company)

Transaction during the year

Nature of Transactions	Holding Company	
	Year ended 31 March 2026	Year ended 31 March 2025
(i) Employee stock based compensation		
Alivira Animal Health Limited, Ireland	10,223	36,725

MOJ & ASSOCIATES * BENGALURU * CHARTERED ACCOUNTANTS

Alivira Animal Health USA LLC
Notes to the financial statements for the year ended 31 March 2026
Amounts in USD ($) unless otherwise stated

12 Earnings per share

Particulars	Year ended 31 March 2026	Year ended 31 March 2025
Net loss for the year as per statement of profit and loss	(5,22,817)	(5,37,305)
Loss per share - Basic	(0.21)	(0.28)
Loss per share - Diluted	(0.21)	(0.28)

13 Control of the Company

Viyash Scientific Limited is the ultimate controlling Company, which is incorporated and domiciled in India.

14 Contingent liabilities and commitments

There are no contingent liability and commitments

15 Segment information

Segments have been identified taking into account the nature of services, the differing risks and returns, the organisational structure and the internal reporting system

Primary segment: Business segment

The Company is mainly engaged in the business of trading and marketing of Pharmaceutical products. Considering the nature of business and financial reporting of the Company, the Company has only one business segment viz; Pharmaceuticals as primary reportable segment. All the activies of the Company are in USA.

16 Previous year's figures have been regrouped / reclassified, wherever necessary, to confirm to the current year's classification.

As per our report of event date

For M O J & ASSOCIATES
Chartered Accountants
ICAI FRN: 015425S

Avneep L Mehta
Partner
Membership no. 225441

Date: 18 May 2026
Place: Banglore

M O J & ASSOCIATES BENGALURU CHARTERED ACCOUNTANTS

Alan Kelly
Authorised Signatory
Vice President

Date: 18 May 2026
Place: Banglore